Tirzepatide vs Semaglutide: Receptor Pharmacology and Head-to-Head Clinical Research

Tirzepatide and semaglutide differ by one receptor. Two randomised head-to-head trials compared them directly: SURPASS-2 and SURMOUNT-5.

By Updated

This is the one comparison in the incretin field that does not have to be assembled from separate trials. Tirzepatide and semaglutide have been randomised against each other twice, in two different populations, with the results published in full — SURPASS-2 in type 2 diabetes and SURMOUNT-5 in obesity without diabetes.

That makes this page shorter on caveats than most comparison pages and longer on specifics. It also makes the remaining caveats sharper, because both head-to-head trials share features — open-label design, and a sponsor that manufactures one of the two compounds — that determine how the results should be read.

What they are

PropertyTirzepatideSemaglutide
Development codeLY3298176NN9535
Compound typeSynthetic modified peptideSynthetic acylated peptide analogue of human GLP-1
Peptide familyGlucagon / secretin peptide superfamily (GIP and GLP-1 receptor ligands)Glucagon / secretin peptide superfamily (GLP-1 receptor ligands)
Primary targetGlucose-dependent insulinotropic polypeptide receptor (GIPR)Glucagon-like peptide-1 receptor (GLP-1R)
Secondary targetsGlucagon-like peptide-1 receptor (GLP-1R)Not established
Receptor familyClass B1 (secretin-like) G protein-coupled receptorsClass B1 (secretin-like) G protein-coupled receptors
Agonist / antagonistAgonist at both receptorsAgonist at the GLP-1 receptor
Highest research phaseApproved; phase 3 programmes and a cardiovascular outcome trial completed and reportedApproved; phase 3 programmes and cardiovascular and kidney outcome trials completed and reported
Regulatory status (United States)Approved as a finished pharmaceutical product. Tirzepatide is the active ingredient of products approved by the U.S. Food and Drug Administration and marketed by Eli Lilly and Company. That approval attaches to those finished products as manufactured, formulated and labelled by their sponsor. It does not attach to tirzepatide as a chemical, and it confers nothing on research-grade material supplied for laboratory use.Approved as a finished pharmaceutical product. Semaglutide is the active ingredient of products approved by the U.S. Food and Drug Administration and marketed by Novo Nordisk. That approval attaches to those finished products as manufactured, formulated and labelled by their sponsor. It does not attach to semaglutide as a chemical, and it confers nothing on research-grade material supplied for laboratory use.
Human trials publishedYesYes

Every value in this table is read from the two compounds’ own library entries when the site is built, so it cannot disagree with them. Nothing here ranks one compound against the other.

Semaglutide is an acylated analogue of human glucagon-like peptide-1, developed by Novo Nordisk and first described in 2015. It is an agonist at a single receptor, the glucagon-like peptide-1 receptor [1].

Tirzepatide is a synthetic 39-residue peptide developed by Eli Lilly and Company under the code LY3298176, first described in 2018. It is a dual agonist at the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor [2].

Both are approved medicines in the United States in defined indications, and both are studied on a once-weekly subcutaneous schedule. Both solve the same pharmacokinetic problem the same way: a fatty acid attached to a lysine side chain binds serum albumin reversibly, protecting the peptide from proteolysis and renal clearance and stretching a half-life of minutes into one of days [1, 2].

Their backbones are not the same, and the difference is not cosmetic. Semaglutide is built on GLP-1. Tirzepatide is built on a GIP backbone that has been engineered to acquire GLP-1 receptor activity as well [2]. The compound that engages two receptors is therefore the one whose parent hormone was the second incretin, not the first.

Receptor and mechanistic differences

Both receptors at issue are class B1, secretin-like G protein-coupled receptors that couple through Gs to raise intracellular cyclic AMP [3]. Both are expressed on pancreatic islet cells; both are also expressed in the central nervous system, and the GIP receptor is additionally distributed widely across peripheral organs [6].

The GLP-1 receptor arm is shared, and its physiology is the best characterised of the two: glucose-dependent insulin secretion, suppression of glucagon secretion, slowing of gastric emptying, and central effects on food intake [4, 5]. Semaglutide's entire pharmacology sits here.

The GIP receptor arm is what tirzepatide adds. GIP is the other incretin hormone, and its receptor was cloned in 1993 and shown to be widely distributed in peripheral organs and the brain [6]. Its role in metabolic pharmacology has been contested for longer than either compound has existed — the reason being that both agonism and antagonism at this receptor have plausible mechanistic rationales, and both have been pursued clinically [21, 22]. Tirzepatide is on the agonist side of that argument.

There is a second, quieter mechanistic difference: the two molecules are not balanced the same way at the receptor they share. Tirzepatide is characterised as an imbalanced dual agonist whose activity at the GIP receptor is comparable to native GIP while its relative activity at the GLP-1 receptor is weaker than native GLP-1 [2]. Semaglutide deliberately traded GLP-1 receptor affinity — approximately three-fold weaker than liraglutide — for much higher albumin affinity [1]. Neither is simply "more potent" than the other at the shared receptor; each was tuned for a different purpose.

Receptors engaged
Semaglutide — GLP-1R only. Tirzepatide — GIPR and GLP-1R [1, 2].
Parent hormone
Semaglutide is built on GLP-1. Tirzepatide is built on a GIP backbone engineered for dual activity [2].
Receptor balance
Tirzepatide, greater relative activity at GIPR than at GLP-1R [2]. Semaglutide, reduced GLP-1R affinity traded for albumin affinity [1].
Half-life strategy
Both use fatty-acid acylation and reversible albumin binding to support a once-weekly schedule [1, 2].
Regulatory position
Both are approved medicines in the United States in defined indications. Approval attaches to a specific compound and a specific indication in each case.

What the research compares

Two randomised trials compared the two compounds directly, and they are the only direct comparisons that exist.

SURPASS-2 randomised 1,879 participants with type 2 diabetes on metformin, 1:1:1:1, to tirzepatide 5, 10 or 15 mg or to semaglutide 1 mg once weekly, open-label, for 40 weeks [11, 24].

SURMOUNT-5 randomised 751 adults with obesity and without type 2 diabetes, 1:1, to the maximum tolerated amount of tirzepatide (10 or 15 mg) or of semaglutide (1.7 or 2.4 mg) once weekly, open-label, for 72 weeks [19, 25].

Three features of both trials govern how they should be read, and none of them is a flaw so much as a boundary. First, both were open-label, which matters most for the reporting of subjective adverse events such as nausea. Second, both were sponsored by the manufacturer of one of the two compounds. Third — and specific to SURPASS-2 — the comparator was semaglutide 1 mg, the amount used in type 2 diabetes at the time, not the higher amount later approved for a different indication.

Outside these two trials the comparison reverts to indirect inference across separate placebo-controlled programmes, which rests on assumptions that randomisation removes. Published systematic analyses of approved incretin mimetics state that limitation explicitly [23].

What the head-to-head human research shows

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

SURPASS-2 — type 2 diabetes, 40 weeks

Population. 1,879 participants with type 2 diabetes on metformin. Mean baseline glycated haemoglobin 8.28%, mean age 56.6 years, mean body mass 93.7 kg [11, 24].

Endpoint and design. Primary endpoint the change in glycated haemoglobin from baseline to week 40. Open-label, with semaglutide 1 mg once weekly as the active comparator [11].

Result. Estimated mean glycated haemoglobin change was −2.01, −2.24 and −2.30 percentage points with tirzepatide 5, 10 and 15 mg against −1.86 with semaglutide. Differences against semaglutide were −0.15 (95% CI −0.28 to −0.03; P = 0.02), −0.39 (95% CI −0.51 to −0.26; P < 0.001) and −0.45 percentage points (95% CI −0.57 to −0.32; P < 0.001). Estimated treatment differences in body mass were −1.9 kg, −3.6 kg and −5.5 kg, P < 0.001 for all [11].

Adverse events. Predominantly gastrointestinal and mild to moderate in both arms: nausea 17–22% with tirzepatide against 18% with semaglutide; diarrhoea 13–16% against 12%; vomiting 6–10% against 8%. Serious adverse events were reported in 5–7% against 3% [11].

Limitations. Open-label; 40 weeks; a comparator used at 1 mg rather than at a higher amount; and a glycaemic primary endpoint, which is a surrogate rather than a clinical outcome.

SURMOUNT-5 — obesity without diabetes, 72 weeks

Population. 751 adults with obesity and without type 2 diabetes [19, 25].

Endpoint and design. Percentage change in body mass at week 72, comparing the maximum tolerated amount of each compound. Open-label, randomised 1:1 [19].

Result. Least-squares mean percentage change in body mass at week 72 was −20.2% (95% CI −21.4 to −19.1) with tirzepatide against −13.7% (95% CI −14.9 to −12.6) with semaglutide, P < 0.001. Least-squares mean change in waist circumference was −18.4 cm against −13.0 cm, P < 0.001 [19].

Limitations. Open-label, which is material for tolerability reporting; sponsored by the manufacturer of one of the two compounds; anthropometric endpoints rather than clinical outcomes; and 751 participants, an order of magnitude smaller than either compound's outcome trials.

What the head-to-head trials do not compare

Neither trial was an outcome trial. Neither counted deaths, myocardial infarctions, strokes or kidney failure, and neither was powered to. On those endpoints the two compounds have only been tested separately, and against different comparators.

Semaglutide's outcome record comprises SUSTAIN-6 in 3,297 participants with type 2 diabetes against placebo, hazard ratio 0.74 for the primary composite [7]; SELECT in 17,604 participants with cardiovascular disease and without diabetes against placebo, hazard ratio 0.80 [14]; and FLOW in 3,533 participants with type 2 diabetes and chronic kidney disease, hazard ratio 0.76 for the composite kidney outcome, stopped early at a prespecified interim [17].

Tirzepatide's is SURPASS-CVOT: 13,299 participants with type 2 diabetes and atherosclerotic cardiovascular disease randomised against dulaglutide 1.5 mg, not against placebo and not against semaglutide. The primary composite occurred in 12.2% against 13.1%, hazard ratio 0.92, 95.3% CI 0.83 to 1.01 — noninferiority met, superiority not demonstrated [20].

An active-comparator noninferiority result and a placebo-controlled superiority result answer different questions. Placing hazard ratios from the two side by side compares the trials' comparators as much as it compares the compounds, which is why no such comparison is drawn here.

Where each has been studied separately

Both compounds have phase 3 or phase 2 records in liver disease, reported against histological endpoints in separate trials: ESSENCE for semaglutide, an interim analysis in the first 800 of 1,197 participants [18], and SYNERGY-NASH for tirzepatide, a phase 2 trial in 190 participants [15]. Tirzepatide has also reported two phase 3 trials in moderate-to-severe obstructive sleep apnoea with obesity, against the apnoea-hypopnoea index [16]. Semaglutide has reported STEP 1 and STEP 2 against anthropometric endpoints [9, 10]. None of these are comparisons; they are parallel records.

What the preclinical research shows

Animal research

The rodent literatures were not designed to compare the two compounds and do not.

Rat work on semaglutide asked where the compound acts. It did not cross the blood-brain barrier, yet reached the brainstem, septal nucleus and hypothalamus through the circumventricular organs, with central c-Fos activation mapped across ten brain areas and analysis pointing to neurons of the lateral parabrachial nucleus. Body-mass reduction occurred without a decrease in whole-body metabolic rate [8]. Mini-pig pharmacokinetics gave a plasma half-life of 46.1 hours after intravenous administration [1].

Tirzepatide's rodent characterisation accompanied its discovery paper and reported the metabolic profile of the dual agonist alongside its in vitro receptor pharmacology [2]. The two sets of experiments used different species, models and endpoints.

Findings described in this section were observed in animals. Nothing in them establishes anything about humans, and nothing in them supports a comparison between the two compounds.

Where the in vitro pharmacology differs

In vitro research

Semaglutide's affinity for the GLP-1 receptor was measured at 0.38 ± 0.06 nM, approximately three-fold weaker than liraglutide, against substantially higher albumin affinity. The discovery paper separates the design levers explicitly: substitutions at positions 8 and 34 secure stability against enzymatic degradation, while the fatty acid moiety and its linker chemistry secure albumin affinity [1].

Tirzepatide was characterised at two cloned human receptors, with activity at the GIP receptor comparable to native GIP and weaker relative activity at the GLP-1 receptor than native GLP-1 [2]. That imbalance is the compound's defining in vitro property and is deliberate.

The two characterisations come from different papers, different assay formats and different reference standards. Even at the receptor they share, the numbers are not interchangeable, and potency at a cloned receptor in a transfected cell line is not a proportional predictor of tissue effect — the albumin binding that defines both molecules is absent from the assay entirely.

Research status of each

Semaglutide is approved in the United States in defined indications and has the deeper clinical-outcome record: cardiovascular outcomes in type 2 diabetes and in cardiovascular disease without diabetes, kidney outcomes in chronic kidney disease, and a phase 3 trial in metabolic dysfunction-associated steatohepatitis [7, 14, 17, 18].

Tirzepatide is approved in the United States in defined indications and has completed a large phase 3 programme in type 2 diabetes and obesity, plus a cardiovascular outcome trial against an active comparator and phase 3 work in a respiratory indication [12, 13, 20, 16].

Both records belong to pharmaceutical development programmes: investigational and approved material manufactured to a regulatory standard, administered under registered protocols in defined populations under clinical supervision. None of it is research into, or evidence about, research-grade material supplied for laboratory use.

Frequently Asked Questions

What is the difference between tirzepatide and semaglutide?
One receptor. Semaglutide is an agonist at the glucagon-like peptide-1 receptor alone [1]. Tirzepatide is a dual agonist at both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor [2]. They are also built on different parent hormones: semaglutide on GLP-1, tirzepatide on a GIP backbone engineered for dual activity.
Have tirzepatide and semaglutide been compared head-to-head?
Yes, twice. SURPASS-2 randomised 1,879 participants with type 2 diabetes on metformin to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg for 40 weeks [11]. SURMOUNT-5 randomised 751 adults with obesity and without type 2 diabetes to the maximum tolerated amount of each compound for 72 weeks [19]. Both were open-label and both were sponsored by the manufacturer of one of the two compounds.
What did the head-to-head trials measure?
Surrogate endpoints, not clinical outcomes. SURPASS-2's primary endpoint was the change in glycated haemoglobin at 40 weeks; estimated mean change was −2.01 to −2.30 percentage points with tirzepatide against −1.86 with semaglutide, with treatment differences of −0.15 to −0.45 percentage points [11]. SURMOUNT-5's endpoint was percentage change in body mass at 72 weeks: −20.2% against −13.7% [19]. Neither trial counted deaths, myocardial infarctions, strokes or kidney failure.
Why does the open-label design of both trials matter?
Because participants and investigators knew which compound was being administered, and the adverse events that dominate both trials are subjective — nausea, diarrhoea, vomiting. Open-label reporting of subjective events is more susceptible to expectation than blinded reporting. It does not invalidate the primary endpoints, which were objective laboratory and anthropometric measures, but it bounds how the tolerability comparison should be read [11, 19].
How do the two compare on cardiovascular outcomes?
They have never been compared on cardiovascular outcomes, and the two outcome programmes are not readable against one another. Semaglutide was tested against placebo — SUSTAIN-6, hazard ratio 0.74 [7], and SELECT, hazard ratio 0.80 [14]. Tirzepatide was tested against dulaglutide 1.5 mg in SURPASS-CVOT, meeting noninferiority with a hazard ratio of 0.92 but not demonstrating superiority [20]. A placebo-referenced result and an active-comparator noninferiority result answer different questions.
Is one of them approved and the other not?
Both are approved medicines in the United States in defined indications. Approval attaches to a specific compound for a specific indication in each case, so the two approvals are separate facts and neither extends to any other compound in the class.
Why is the GIP receptor arm contested?
Because both agonism and antagonism at the GIP receptor have plausible mechanistic rationales in metabolic research, and both have been pursued clinically. The published arguments for each are set out in parallel review articles [21, 22]. Tirzepatide sits on the agonist side of that question; the argument itself predates the compound.

References

  1. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide Journal of Medicinal Chemistry; 2015. PMID 26308095 doi:10.1021/acs.jmedchem.5b00726
  2. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept Molecular Metabolism; 2018. PMID 30473097 doi:10.1016/j.molmet.2018.09.009
  3. Biology of incretins: GLP-1 and GIP Gastroenterology; 2007. PMID 17498508 doi:10.1053/j.gastro.2007.03.054
  4. The physiology of glucagon-like peptide 1 Physiological Reviews; 2007. PMID 17928588 doi:10.1152/physrev.00034.2006
  5. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 Cell Metabolism; 2018. PMID 29617641 doi:10.1016/j.cmet.2018.03.001
  6. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain Endocrinology; 1993. PMID 8243312 doi:10.1210/endo.133.6.8243312
  7. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes The New England Journal of Medicine; 2016. PMID 27633186 doi:10.1056/NEJMoa1607141
  8. Semaglutide lowers body weight in rodents via distributed neural pathways JCI Insight; 2020. PMID 32213703 doi:10.1172/jci.insight.133429
  9. Once-Weekly Semaglutide in Adults with Overweight or Obesity The New England Journal of Medicine; 2021. PMID 33567185 doi:10.1056/NEJMoa2032183
  10. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial The Lancet; 2021. PMID 33667417 doi:10.1016/S0140-6736(21)00213-0
  11. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes The New England Journal of Medicine; 2021. PMID 34170647 doi:10.1056/NEJMoa2107519
  12. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial The Lancet; 2021. PMID 34186022 doi:10.1016/S0140-6736(21)01324-6
  13. Tirzepatide Once Weekly for the Treatment of Obesity The New England Journal of Medicine; 2022. PMID 35658024 doi:10.1056/NEJMoa2206038
  14. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes The New England Journal of Medicine; 2023. PMID 37952131 doi:10.1056/NEJMoa2307563
  15. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis The New England Journal of Medicine; 2024. PMID 38856224 doi:10.1056/NEJMoa2401943
  16. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity The New England Journal of Medicine; 2024. PMID 38912654 doi:10.1056/NEJMoa2404881
  17. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes The New England Journal of Medicine; 2024. PMID 38785209 doi:10.1056/NEJMoa2403347
  18. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis The New England Journal of Medicine; 2025. PMID 40305708 doi:10.1056/NEJMoa2413258
  19. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity The New England Journal of Medicine; 2025. PMID 40353578 doi:10.1056/NEJMoa2416394
  20. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes The New England Journal of Medicine; 2025. PMID 41406444 doi:10.1056/NEJMoa2505928
  21. A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity Diabetes; 2025. PMID 40521890 doi:10.2337/dbi24-0026
  22. GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale Diabetes; 2025. PMID 40521869 doi:10.2337/dbi24-0027
  23. Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials Diabetes, Obesity and Metabolism; 2025. PMID 40212008 doi:10.1111/dom.16398
  24. A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes. NCT03987919
  25. A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities. NCT05822830

Every identifier above is resolved against PubMed, Crossref or ClinicalTrials.gov at build time, and the title returned by the register is compared with the title stored here. A page does not publish if a reference fails to resolve.

Research-Use Information

For in vitro research use only. This material is a laboratory reagent. It is not a drug, food, dietary supplement, or cosmetic and is not for human or veterinary use, including ingestion, injection, or any other administration. No information on this page describes or implies any effect in humans or animals. Sold only to researchers under our Terms of Sale.